WASHINGTON ( January 15 ) -- Today, President Trump unveiled  his "Great Healthcare Plan," including a proposal for Congress to codify Most Favored Nation  (MFN) drug pricing into law. This policy would import foreign government price controls into the U.S. market and threaten the innovation ecosystem responsible for delivering new cures and lifesaving treatments.    Incubate's executive director, John Stanford, issued the following statement in response to the announcement:

2025 brought no shortage of new ideas in Washington to reshape how the United States pays for medicines. From Most Favored Nation  (MFN) proposals to executive actions and broader drug pricing reforms, the policy debate moved quickly, with major implications for patients, investors, and the future of biomedical innovation.  Throughout the year, Incubate stayed at the cutting edge of that dialogue, bringing a consistent focus to what matters most: protecting access today while

WASHINGTON (December 19) –   Today, the Center for Medicare and Medicaid Innovation (CMMI) announced a proposed series of Medicare drug pricing demonstrations affecting some Part B  and Part D  medicines, respectively. The Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) demonstrations would significantly restructure Medicare drug reimbursement and coverage, pegging Medicare Part B and Part D drug prices to those

WASHINGTON ( December 2 ) -- Yesterday, the United States and the United Kingdom announced  a new agreement on pharmaceutical pricing as part of the Economic Prosperity Deal (EPD). The agreement is expected to increase the U.K.'s valuation of new medicines and expand its long-term investment in innovative therapies. The United States, in turn, committed to exempt U.K.-origin pharmaceuticals from any future Section 232 tariffs and to refrain from targeting U.K. pricing polici

WASHINGTON ( Sep 30 ) -- Today, the Trump administration announced its first agreement with a manufacturer to bring most-favored-nation...

Incubate executive director John Stanford was recently featured in an Inside Health Policy  article by reporter Gabrielle Wanneh on the pressures facing the pharmaceutical industry under President Trump's Most Favored Nation (MFN) drug pricing proposal, among other policy headwinds.  While companies are publicly emphasizing growth, Stanford cautioned that beneath the surface the investment ecosystem is being reshaped by policies like the Inflation Reduction Act's pill penalty

WASHINGTON, D.C. ( July 31 ) -- Today, the Trump administration announced  a 60-day deadline for 17 leading pharmaceutical manufacturers...

On June 24, Incubate executive director John Stanford joined Punchbowl News for a discussion  on the future of medicine. The culmination...

The White House and some members of Congress have recently proposed  adopting a "Most Favored Nation"   (MFN) pricing model for Medicaid...